EYEG - EyeGate Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1893
-0.0037 (-1.92%)
At close: 3:57PM EDT

0.1900 -0.00 (-0.47%)
After hours: 5:17PM EDT

Stock chart is not supported by your current browser
Previous Close0.1930
Open0.1965
Bid0.1893 x 1100
Ask0.1900 x 900
Day's Range0.1850 - 0.2010
52 Week Range0.1850 - 0.6400
Volume137,691
Avg. Volume499,576
Market Cap8.646M
Beta (3Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Allakos (NASDAQ: ALLK ) shares were up 112.6% ...

  • Benzinga

    Eyegate Pharmaceuticals Receives FDA Approval To Begin PE Pilot Study

    Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares are trading higher after the company received FDA approval to initiate its follow-on pilot study for punctate epitheliopathies (PE). The study will use the Ocular Bandage Gel eye drop to treat patients with PE, which can be associated with dry eyes. "We are excited to get underway with another clinical study and very pleased with our continued cooperation and collaboration with the FDA," said CEO Stephen From.

  • Zacks Small Cap Research

    EYEG: FDA Approves IDE. We Like Chances of Success of Upcoming OBG-PRK Pivotal Study

    By Brian Marckx, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT FDA Approves IDE for OBG-PRK Pivotal Study, Topline Results Expected Later This Year… The major recent news on the operating front was ...

  • Zacks Small Cap Research

    EYEG: EYEG Submits IDE to FDA Seeking Approval to Commence Pivotal PRK Study

    This morning EyeGate (EYEG) announced that they submitted an Investigational Device Exemption (IDE) application to the FDA seeking approval to commence a pivotal study for OBG in PRK. FDA turnaround is anticipated in approximately 30 days. EYEG notes that while they wait for the U.S. regulatory agency’s answer, they will continue with the initiation of the planned study which, if successful, is expected to be used as primary support for a De Novo filing.

  • Zacks Small Cap Research

    EYEG: Our Take On EYEG Moving Towards OBG-PRK Pivotal Study

    EyeGate (EYEG) announced financial results for their fourth quarter ending December 31st. For the full year, revenue was $1.7M, all of which relates to recognition of milestones from the EGP-437 development agreements with Bausch Health Companies (BHC). In the 10-K, EYEG discloses that they received a notice of termination from BHC on December 14th notifying them that BHC is voluntarily terminating these agreements effective March 14, 2019.

  • Zacks Small Cap Research

    EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE?

    EyeGate (EYEG) announced Q3 financial results and provided a business update. To-date, EYEG has received $13.8M in upfront and milestones under the two agreements, including ~$300k in the most recent quarter. While the yoy decrease reflects a change in activity from the relatively large EGP-437 trials to the smaller OBG studies, the qoq increase is a result of continued progression of both OBG programs.

  • Zacks Small Cap Research

    EYEG: Focus Is On OBG As U.S. Pilot Studies Fully Enrolled. Data Expected Q4. EGP-437 Ph3 AE Data Disappoints

    EyeGate (EYEG) reported Q2 2018 financial results and provided a business update. Through Q2, EYEG collected $13.5M from Valeant related to upfront payments and development milestones associated with the development agreements for EGP-437 in anterior uveitis and post-cataract surgery. In terms of how these payments are recognized on EYEG’s financial statements, as a reminder an updated FASB standard governing revenue-recognition for contracts with customers resulted in a $9.5M adjustment to EYEG’s deferred revenue balance (as of Jan 1, 2018) – this is solely an accounting adjustment with no cash effect.